Podcasts about drug prices

A federal judge in Maryland questioned the Trump administration about its continued refusal to retrieve a mistakenly deported man from an El Salvador prison, President Trump signed an executive action that aims to lower drug prices for Americans, and the President threatened to remove Harvard's tax exempt status.Want more comprehensive analysis of the most important news of the day, plus a little fun? Subscribe to the Up First newsletter.Today's episode of Up First was edited by Anna Yukananov, Scott Hensley, Steven Drummond, Janaya Williams and Mohamad ElBardicy. It was produced by Ziad Buchh, Nia Dumas and Christopher Thomas. We get engineering support from Arthur Laurent. And our technical director is David Greenburg.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Steve Forbes calls out the unfair trade practices that sees U.S. citizens subsidizing the pharmaceutical bills of other countries—and lays out the desperately needed reforms to make things right.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to CPI Day - this one, in the midst of a head-spinning market turmoil. This moves the CPI report back a little bit in terms of its importance, but the underlying inflation pressures and the effect on prices of tariffs, going forward, are a big part of the reason for the market turmoil. Uncertainty implies lower prices for risky assets, and we are seeing that. It also has implications for inflation itself, through velocity, and for the hurdle to make policy moves as a central banker. Join the Inflation Guy as he untangles today's CPI report, and a lot of the surrounding noise.   NOTES Episode callback: “Ep. 137: Drug Prices and the Most-Favored-Nation Clause” https://inflationguy.podbean.com/e/ep-137-drug-prices-and-the-most-favored-nation-clause/ Blog for last month's CPI: “Inflation Guy's CPI Summary (February 2025)” (https://inflationguy.blog/2025/03/12/inflation-guys-cpi-summary-february-2025/ ) To Subscribe to Quarterly Inflation Outlook: https://inflationguy.blog/shop/    To Subscribe for free to the blog: https://inflationguy.blog/ Check out the website! https://www.EnduringInvestments.com/  

Dr. Sterling Elliott, clinical pharmacist at Northwestern Medicine and assistant professor of orthopedics at Feinberg School of Medicine, joins Lisa Dent to discuss a variety of prescription drug topics including the impact that the latest tariffs will have on prescription drug prices. Then, as always, Dr. Elliott answers questions from listeners.

The pricing and distribution of pharmaceuticals is one of the most opaque major pricing systems in the United States. There are oligopolies at the wholesaler level and at the Pharmacy Benefits Manager (PBM) level, which completely control consumer-level pricing. The Inflation Guy explains this system, which has attracted the ire of President Trump in the past since Americans also pay much higher prices for medications than consumers in other countries pay for the same medications; in 2020 President Trump called for a Most-Favored-Nation clause to be applied to drug companies but his first term ended before he could pursue it. Expect the topic to come up again...and this time, you'll understand why it's a great cudgel but doesn't really address the problem!   NOTES Inflation Guy Blog Post: “Drug Prices and Most-Favored-Nation Clauses: Considerations” https://inflationguy.blog/2020/08/25/drug-prices-and-most-favored-nation-clauses-considerations/ Very important blog post: “What Makes a Stable Coin Stable?” https://inflationguy.blog/2024/10/31/what-makes-a-stable-coin-stable/ Blog for this month's CPI: “Inflation Guy's CPI Summary (February 2025)” (https://inflationguy.blog/2025/03/12/inflation-guys-cpi-summary-february-2025/ ) To Subscribe to Quarterly Inflation Outlook: https://inflationguy.blog/shop/   Now just $29.99/quarter! To Subscribe for free to the blog: https://inflationguy.blog/ Check out the website! https://www.EnduringInvestments.com/

It's Thursday, March 6th, 2025. This is Nelson John, let's get started.  ITC Hotels' Rough Debut January 29 was supposed to be a landmark day for ITC Hotels as it began trading independently. However, shares debuted nearly 30% below the implied price, dampening initial enthusiasm. Despite this, analysts remain bullish, valuing the company between ₹42,500-₹62,000 crore. ITC Hotels aims to expand to 200 hotels with 18,000 rooms in five years, relying on managed properties. However, investors worry about its limited owned-hotel pipeline. As competitors like IHCL and Marriott ramp up expansion, ITC Hotels must carve out its niche in a booming industry. Coforge's Record-Breaking Deal Coforge Ltd soared 8% after securing a record 13-year, $1.56 billion deal with US travel tech giant Sabre Corp. This long-term contract ensures strong revenue visibility for FY26, even as tech budgets shrink. Coforge also acquired Rythmos Inc. for $48.7 million and TMLabs for $12.5 million, further expanding its portfolio. A 1:5 stock split was announced to boost liquidity. However, Sabre's $5.1 billion debt raises cash collection concerns. Despite this, Coforge has outperformed peers, with its December order book reaching $1.4 billion—up 40% YoY. Tesla, Tariffs & Trump India's sky-high auto tariffs—up to 110%—have kept foreign automakers like Tesla out, despite Elon Musk's repeated attempts to enter the market. Now, US President Donald Trump has joined the fight, slamming India's “unfair” tariffs and threatening retaliatory action. As trade negotiations intensify, India has begun cutting duties on luxury vehicles—a possible opening for Tesla. With Trade Minister Piyush Goyal in the US for talks, the world watches to see if India will open its doors to global carmakers or protect its domestic industry. Cancer Drug Prices Set to Fall Cancer treatment in India is notoriously expensive, with some drugs costing up to ₹2 lakh per month. That's changing, thanks to domestic production under the government's PLI scheme. Leading pharma firms like Sun Pharma, Cipla, and Biocon are now manufacturing key cancer drugs, significantly cutting prices. For example, Trastuzumab, once ₹70,000 per month, now costs ₹12,000. More price reductions are expected as local production scales up. The initiative not only benefits Indian patients but also strengthens India's role as the “pharmacy of the world,” with exports to South America and Africa. Rupee Rises Amid Market Rally The rupee strengthened by 19 paise to close at 87.00 against the US dollar, supported by a rally in domestic equities, a weaker dollar, and falling crude oil prices. Volatility remained high, with the currency fluctuating between 86.93 and 87.20. Meanwhile, the dollar index slipped 0.79% amid Trump's escalating tariff moves. Brent crude also declined 0.75% to $70.51 per barrel. Markets responded positively, with the Sensex surging 740 points to 73,730 and the Nifty rising 255 points to 22,337. However, FII outflows and ongoing trade uncertainties could limit further rupee gains.

Emily Lampkin, spokeswoman for Pharmaceutical Reform Alliance. POTUS Address to Congress. Prescription drug prices, what needs to be done?

The Trump administration is showing cracks just weeks in, with prescription drug prices soaring, 9/11 first responder funding cuts (later reversed after public outcry). Tristan analyzes Germany's recent election where the far-right AFD failed to gain power, explains how social media activism successfully pressured the administration to restore 9/11 health funding, and breaks down why Republicans in purple districts are increasingly vulnerable defending unpopular policies. Plus: why Elon Musk's EV charging station removal hilariously backfires on his own interests.

It's the monthly inflation report for January's CPI, and this one was surprising. It would have been alarming, except that we have been through five years of inflation unlike anything we had seen since the 1980s. So, we're jaded. The Inflation Guy walks through today's report and considers wildfires, tariffs, and most-favored-nation status. A tour de force!   NOTES Very important blog post: “What Makes a Stable Coin Stable?” https://inflationguy.blog/2024/10/31/what-makes-a-stable-coin-stable/ Blog for this month's CPI: “Inflation Guy's CPI Summary (January 2025)” (https://inflationguy.blog/2025/02/12/inflation-guys-cpi-summary-january-2025/ ) Blog on "Drug Prices and Most-Favored-Nation Clauses: Considerations" from August 2020 https://inflationguy.blog/2020/08/25/drug-prices-and-most-favored-nation-clauses-considerations/ To Subscribe to Quarterly Inflation Outlook: https://inflationguy.blog/shop/   Now just $29.99/quarter! To Subscribe for free to the blog: https://inflationguy.blog/ Check out the website! https://www.EnduringInvestments.com/

We’re kicking off a new reporting project about how much we pay for our medicine — and what we can maybe do about it — and we want to hear your stories. Because: Getting a case of sticker shock with a prescription happens all the time. So we’re asking: What have you done — or tried to do — to get the medicines you need at prices you can afford? And what did you learn that might be useful for other people to know? Maybe you learned a strategy that actually WORKED for you. Like using a coupon or ordering drugs from online pharmacies — even pharmacies in other countries. Maybe it was, “Man, I learned about a new way I’m getting screwed.” However things went, tell us about it here: armandalegshow.com/drugs Your story can be short or long, scary or uplifting – whatever you’ve gone through to get your meds, whether it worked or not, we want to hear about it. The more we learn about these strategies, and about new ways we’re getting beat up, the more we can work together to do something about it. And over the next couple of months, we’ll dig into everything you bring us, call up some experts, and start bringing you what we’re learning. Meanwhile, if you could use some tips right now for getting a better price for your prescription, we’ve just posted a batch to our First Aid Kit newsletter – check it out here. Fair warning: It’s a collection of band-aids — that’s what you find in a first aid kit — but it’s a start. Here’s a transcript of this episode. Send your stories and questions. Or call 724 ARM-N-LEG. Of course we’d love for you to support this show.See omnystudio.com/listener for privacy information.

-- On the Show: -- A look at the Trump voters who will be damaged the most by Donald Trump's policies -- Trump's health is going viral again, and we take a look at the reasons why -- By rescinding a Biden-era order on prescription drug prices, Donald Trump will cause drug prices to go up -- Florida Governor Ron DeSantis gets shut down by the Florida legislature, and he does not take it well -- Secretary of Homeland Security Kristi Noem is so late to her own swearing-in due to a late-arriving bible that Vice President JD Vance leaves without swearing her in -- This week's Friday Feedback, one day early -- On the Bonus Show: Plane crash in DC, Menendez sentenced to 11 years, and much more... ☕ Cambio Roasters: Get 20% off with code PAKMAN at https://cambioroasters.com

U.S. Rep. Raja Krishnamoorthi (D-IL 8th) talks with Lisa Dent and Steve Bertrand about the fight to reduce drug prices in the United States and what is currently driving those prices up. In addition, he gives the latest update on the status of TikTok. Then, he discusses the legitimacy of a number of President Trump’s […]

For Episode 51 of the Astonishing Healthcare podcast, we spoke with Nick Opalich, CEO of HospiceChoice Rx. We learned about how end-of-life care is evolving in the U.S., including the roles pharmacy and technology play in the hospice industry. Nick and host Justin Venneri discuss some similarities between the hospice pharmacy benefit management (PBM) and commercial PBM spaces, such as the importance of a great pharmacy network and independent pharmacies, why the drug price index matters (NADAC vs. AWP), medication access, and disconnected systems.A former pharmacy owner himself, Nick explains the importance of helping hospice providers control drug spend, which is usually the second highest cost behind labor for providers, and reimbursement trends/pressure. He also touches on dispense fees, the potential to improve ePrescribing, and leveraging AI for enhanced reporting.Related ContentWhat is NADAC & How Does It Differ From AWP?Pharmacy Benefits 101: The Importance of the NetworkFor ReferenceHospice industry Facts & Figures (NHPCO, 2024)Thank you for listening, and check out Capital Rx Insights for more, including this episode's transcript!

Get the facts, without the spin. UNBIASED offers a clear, impartial recap of US news, including politics, elections, legal news, and more. Hosted by lawyer Jordan Berman, each episode provides a recap of current political events plus breakdowns of complex concepts—like constitutional rights, recent Supreme Court rulings, and new legislation—in an easy-to-understand way. No personal opinions, just the facts you need to stay informed on the daily news that matters. If you miss how journalism used to be, you're in the right place. In today's episode: DHS Issues New Directives Allowing Immigration Enforcement in "Sensitive Places" and Rescinding Biden's Parole Program (0:27) ICE Starts Conducting Raids in Major U.S. Cities (10:49) Pentagon to Send More Troops to Southern Border (13:36) Laken Riley Act Passes Congress, Heads to Trump's Desk (14:14) New Affidavit Against Pete Hegseth Debunked By Ex-Wife; Will He Be Confirmed? (17:02) Trump Pardons Silk Road Founder, Ross William Ulbricht (20:49) Big Tech Companies Announce New $500B AI Investment, Stargate (24:06) Trump Does NOT Repeal Equal Employment Opportunity Act; This is What He Actually Did (25:56) Trump's Birthright Citizenship Executive Order Blocked by Judge; New Filing Shows Trump's Arguments (31:35) HHS Dept. Orders Temporary Pause on Communications (35:16) Quick Hitters: Biden's Letter to Trump Revealed, New Fire Ignites in LA County, Trump Picks Director of Secret Service, Netflix Raising Prices, Couples Sues JetBlue After Ice Falls from Plane, Rare Winter Storms Bring Snow to Southeast, Trump's Nominee for CIA Director Confirmed by Senate (38:05) Rumor Has It: Is ICE Offering $750 Reward for Turning in Illegal Immigrants? Did Trump Rescind Biden's Order Lowering Drug Costs? Are Barack Obama and Jennifer Aniston Dating? Is Meta Causing IG Accounts to Automatically Follow Trump and Vance? (41:53) Good News of the Week (45:55) Listen/Watch this episode AD-FREE on Patreon. Watch this episode on YouTube. Follow Jordan on Instagram and TikTok. All sources for this episode can be found here.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Prescription drug prices have been getting quite expensive over the years, particularly for those on Medicare and fixed incomes. However, the government is here to help! Has government price negotiations worked and what can we expect going forward?

Prescription drug prices have been getting quite expensive over the years, particularly for those on Medicare and fixed incomes. However, the government is here to help! Has government price negotiations worked and what can we expect going forward?

Wednesday's third hour.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly projects a revenue miss for 2024 due to lower-than-anticipated sales of glp-1 blockbusters Mounjaro and Zepbound, causing their shares to drop by as much as 8%. Despite pressure to make a deal, Biogen executives refuse to do so out of desperation. The JPM25 conference featured presentations from Roche, Amgen, Merck, Lilly, and Biogen detailing their growth strategies. Keros fully terminates a mid-stage study on pulmonary arterial hypertension, potentially facing challenges ahead. AGC Biologics offers scale-down data for gene of interest candidates to accelerate timelines. Other news includes questions about accelerated approval for Biogen and Sarepta drugs, lessons learned from Neuropsych's stumbles, and increased drug prices by pharmacy benefit managers. Additionally, Lykos loses board directors after an FDA rejection, while biopharma deals start flowing at JPM25.Biogen executives, despite investor and analyst pressure, are not desperate to make a deal at JPM25. The biopharma industry saw a flood of deals at the event, with companies like Eli Lilly, GSK, and Gilead announcing billion-dollar deals. Seaport is learning from Neuropsych's mistakes amidst renewed interest in the field. The top VC raises in biotech for 2024 were highlighted, showing a significant increase in funding for the industry. J&J made a major neuro play with a $14.6 billion buyout, while Biogen submitted an offer to buy partner Sage. Overall, the industry sentiment has been reinvigorated by the flurry of deals at JPM25.

Democrats and Republicans in the House and Senate successfully negotiated an enormous end-of-Congress health package, including bipartisan efforts to address prescription drug prices — only to see it blown up at the last minute after Elon Musk and President-elect Donald Trump applied pressure. Meanwhile, the Supreme Court accepted its first abortion-related case of the term, and the attorney general of Texas sued a doctor in New York for prescribing abortion pills to a Texas patient. Alice Miranda Ollstein of Politico, Jessie Hellmann of CQ Roll Call, and Victoria Knight of Axios join KFF Health News' Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF President and CEO Drew Altman about what happened in health policy in 2024 and what to expect in 2025.Plus, for “extra credit,” the panelists suggest health policy stories they read this week that they think you should read, too:Julie Rovner: Vox.com's “The Deep Roots of Americans' Hatred of Their Health Care System,” by Dylan Scott. Alice Miranda Ollstein: KFF Health News' “Native American Patients Are Sent to Collections for Debts the Government Owes,” by Katheryn Houghton and Arielle Zionts. Jessie Hellmann: KFF Health News' “How a Duty To Spend Wisely on Worker Benefits Could Loosen PBMs' Grip on Drug Prices,” by Arthur Allen. Victoria Knight: Bloomberg News' “The Weight-Loss Drug Gold Rush Has a Dangerous Prescription Problem,” by Madison Muller. Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Private equity firms Blackstone and Bain Capital are close to finalizing a potential $3 billion deal for Mitsubishi's pharma unit, Mitsubishi Tanabe Pharma. In other news, five drugs have been flagged for unjustified price hikes in 2023 by the Institute for Clinical and Economic Review. Incyte and Iteos are cutting drug candidates from their cancer pipelines due to disappointing data, while the FDA advisory committee has called for more research on Moderna's RSV vaccine after safety issues arose. Layoffs have been announced at Intercept and Editas, and there has been a slowdown in M&A activity in the pharma industry this year. US Pharmacopeia is looking for expert volunteers to work on medicine quality challenges.

In this week's episode: We dive into the complexities of drug pricing and Medicare reforms, exploring how the Inflation Reduction Act impacts prescription costs. Join us as Dr. Lindsey Elmore breaks down key changes and discusses her passion for making healthcare more affordable. Listen to this episode if you want to understand how drug prices are set and what's being done to lower them in the U.S.Topics covered in this episode:Affordable Healthcare and Prescription DrugsDiplomat in Pharmacy LawInflation Reduction Act OverviewDrug Price Negotiation DetailsMedicare Drug Pricing ReformsCost of Insulin and VaccinesBiosimilars and Orphan DrugsU.S. vs. International Drug PricesFuture of Drug Pricing ReformsWe hope you enjoyed this episode. If you would like to be a supporter of the show, head to www.lindseyelmore.com/supporter Your contribution helps us to bring the best guests into our interview chair. Thank you for listening. Come check us out at www.spreaker.com/show/the-lindsey-elmore-showBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-lindsey-elmore-show--5952903/support.

Send us a textIt's no secret that medical drug prices have been out of control for most Americans.However, one hospital group has a novel idea to control drug spending.Blue Shield of California is bypassing PBMs by negotiating directly with the manufacturer of a biosimilar for Humira.Is this a one-off experiment or the start of a bigger trend that can drive industry-wide impact?In this episode of CareTalk, David E. Williams and John Driscoll discuss these price negotiation tactics and what they see as the long-term results of Blue Shield of California's attempt to lower pharmaceutical prices.This episode is brought to you by BetterHelp. Give online therapy a try at https://betterhelp.com/caretalk and get on your way to being your best self.As a BetterHelp affiliate, we may receive compensation from BetterHelp if you purchase products or services through the links provided.TOPICS(0:34) Sponsorship(1:50) Understanding the Complex Nature of Deals with PBMs(2:40) Examining the Humira Deal(3:18) Is the Humira Deal a Trend in Healthcare?(5:43) Will Deals Like Humira Lower Drug Costs?(7:30) Will Patients See Lower Drug Costs?(9:58) How PBMs Factor into Lowering Drug Costs(11:58) The Investor's Perspective on the Blue Shield Deal(13:20) How Patients Factor into Drug Negotiations(16:48) Exploring Cost Plus's Pricing Deals(20:30) PBMs, Inflation, and the Future of Drug Costs

U.S. representative for Illinois's 13th congressional district Nikki Budzinski sits-down with Megan Lynch for an interview covering her opposition to Nippon Steel's acquisition of US Steel; investment in storm-water management in the Metro-East; & the high costs of prescription drugs.

So far, buying medicines in India has been a complete minefield. Allow me to elaborate with the help of a completely plausible hypothetical scenario. Say you catch the flu one day and need 75 mg of the antiviral drug Oseltamivir. More often than not, we don't really check the price tag of these drugs. But what if I told you the prices can swing anywhere between Rs 30 and Rs 125 per capsule, depending on the manufacturer and the doctor prescribing it. Now, variable pricing is not really a revelation. It's a pretty common practice. The government caps the price of nearly 400 essential drugs through the National List of Essential Medicines. But that's where the oevrsight ends. Generally, non-essential drugs remain outside this price cap. The National Health Authority, the body which runs India's public health insurance scheme, Ayushman Bharat, is now looking for digital pharmacy partners to promote pricing transparency. The aim is to tackle this overcharging crisis. So in September, it went ahead and enlisted Marg ERP, a leading provider of pharmacy inventory software as one such partner. Now Kaushal Shah, founder of Evitalrx, revealed that even his cloud-based pharma software firm is on track to join the initiative in the coming weeks.But here's the thing. This one click solution is still a long way off. Tune in. Don't forget to send us your recommendation for this Thursday's Unwind segment. The theme is “your favourite murder mystery.” Send them to us on WhatsApp as a voice note or as a text message. The number is +9189711-08379 Daybreak is produced from the newsroom of The Ken, India's first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.

Pharmacy Benefit Managers (PBMs) are powerful, unseen middlemen impacting drug prices in a big way. The debate is over whether they're saving you money or costing you money— and possibly costing lives.Order Sharyl's new bestselling book: “Follow the $cience.” Subscribe to my two podcasts: “The Sharyl Attkisson Podcast” and “Full Measure After Hours.” Leave a review, subscribe and share with your friends! Support independent journalism by visiting the new Sharyl Attkisson store.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, we sit down with one of the most influential figures in government today: Federal Trade Commission Chair Lina Khan. As the youngest FTC chair to ever be appointed, during her tenure the FTC has pushed to ban non-compete agreements, filed lawsuits against healthcare companies engaging in anti-competitive practices, and strengthened the Health Breach Notification Rule (HBNR) to protect sensitive health data.We cover:- The FTC's role in healthcare and how it compares to other sectors- The impact of consolidation and vertical integration in the healthcare industry- The agency's efforts to combat rising drug prices, including the recent actions against major PBMs- The controversial "Orange Book" patent challenges and their implications for drug innovation- The nationwide ban on non-compete agreements and its potential effects on doctors- Chair Khan's vision for the future of competition law and its application to healthcareSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Here's Episode 105 of Michigan's premier progressive podcast. 00:00-18:17: VEEP Recap/MAGA Attacks Immigrants & Abortion Rights The first segment features Pat Johnston giving his review of the Vice Presidential Debate between Democratic Minnesota Gov. Tim Walz and MAGA Republican Dude-Bro J.D. Vance. Pat highlights where Walz scored some major points, and where he fell short, in his debate against Vance. Pat also talks about how the Dear Leader Trump/Vance attacks on immigrants is leading to violent threats.  18:18-40:48: Interview w/ Amanda Mazur on Abortion Rights Our guest this week is Amanda Mazur, who's an abortion rights activist as well as the Vice President of Northwest Michigan For Reproductive Freedom. Amanda gives her takes on how abortion was covered during the Veep debate, and she shares thoughts on how MAGA Republicans are definitely not "pro-family," and how progressives and Democrats should talk about abortion rights this election year.  40:49-46:11: Last Call: Mike Rogers Wants Higher Drug Prices In the "Last Call," Pat talks about how MAGA Michigan Republican U.S. Senate candidate "Florida" Mike Rogers is "passionately against" allowing Medicare to negotiate lower prescription drug prices. He criticizes Democratic U.S. Senate candidate, and Michigan congresswoman, Elissa Slotkin's backing of the Inflation Reduction Act, which gave Medicare the power to lower the prices of different prescription drugs in the future. Let's see how the voters react to "Florida" Mike's stance on that one.  46:12-48:28: Ending/Go Tigers! Please, subscribe to the podcast, download each episode, and give it a good review if you can! leftoflansing@gmail.com Left of Lansing is now on YouTube as well! leftoflansing.com

If you're using weight loss injections to drop pounds, US Senators have been grilling one of the drug makers about why it costs almost $1349 a month in the United States to take the drug -- compared to $265/month in Canada -- and you won't believe the bargain price Germans get it for. Dave and Debbie discuss the cost of weight loss and speak with Adam Gardiner, KSL @ Night Host, who joins as the State Director for Pharmaceutical care management association to speak on the issue.

A group of obscure yet powerful players in the prescription drug industry are under the microscope. On Tuesday, at a Senate hearing in D.C., the head of pharmaceutical giant Novo Nordisk blamed the health insurance industry and pharmacy benefit managers, or PBMs, for allegedly making products like the weight loss drug Ozempic way more expensive in the U.S. than it is in other countries. A few days before that, the Federal Trade Commission sued three of the country's largest PBMs for allegedly using unfair tactics to artificially inflate the price of insulin. So what exactly are PBMs and how do they work? In an episode that aired two years ago, we explain how the answer involves secret deals and double agents. Related episodes: Who can and cannot get weight loss drugs (Apple / Spotify) New drugs. Cheaper drugs. Why not both? (Apple / Spotify) For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at plus.npr.org. Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Send us a textReady to unravel the mystery behind sky-high drug prices? Join Dr. Michael Koren, a top-tier cardiologist and medical researcher, as he dissects the factors driving the pharmaceutical industry's steep costs. From the firm grip of patent protection to the complex role of pharmacy benefit managers (PBMs) in price negotiations, Dr. Koren illuminates the multifaceted challenges of making medications more affordable. Recording Date: September 23, 2024Be a part of advancing science by participating in clinical research.Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInWant to learn more checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Montanans on Medicare could see big savings on prescription drugs next year.

Joe Selvaggi talks with Bill Smith, Director of the Life Sciences Initiative at Pioneer Institute, about the Inflation Reduction Act's impact on drug pricing negotiations and its potential effects on drug development, consumers, and taxpayers.

Joe Selvaggi talks with Pioneer Institute Director Bill Smith about the Inflation Reduction Act's impact on drug pricing negotiations and its potential effects on drug development, consumers, and taxpayers.

  The Friday Five for August 23, 2024: Ritter Insurance Marketing Summits Next Week Instagram Testing Rectangular Profile Grid FTC Ban on Noncompete Agreements Overturned "Time is Money" Initiative from Biden-Harris Administration CMS Announces First 10 Part D Negotiated Drug Prices   Contact the Agent Survival Guide Podcast! Email us ASGPodcast@Ritterim.com or call 1-717-562-7211 and leave a voicemail.   Register for Ritter Insurance Marketing Annual Summits: https://summits.ritterim.com/   Instagram Testing Rectangular Profile Grid: Hutchinson, Andrew. “Instagram Chief Flags Coming Changes to Profile Grid Displays.” Social Media Today, Social Media Today, 18 Aug. 2024, www.socialmediatoday.com/news/instagram-chief-flags-coming-changes-profile-grid-displays/724532/. Moon, Mariella. “Instagram's Experimental Profile Grid Has Rectangular Images Instead of Squares.” Engadget, Engadget, 17 Aug. 2024, www.engadget.com/social-media/instagrams-experimental-profile-grid-has-rectangular-images-instead-of-squares-160007086.html. Mishra, Prakruti. “Instagram Explores Vertical Profile Grid in Shift from Classic Squares.” Business Standard, Business Standard, 19 Aug. 2024, www.business-standard.com/technology/tech-news/instagram-explores-vertical-profile-grid-in-shift-from-classic-squares-124081900317_1.html. Peters, Jay. “Instagram Is Testing Vertical Profile Grids - and Knows That Might Mess up Layouts.” The Verge, The Verge, 16 Aug. 2024, www.theverge.com/2024/8/16/24222022/instagram-vertical-profile-grids-mess-up-layouts.   FTC Ban on Noncompete Agreements Overturned: “FTC's Bid to Ban Noncompete Agreements Rejected by Federal Judge in Texas.” Dallas News, 21 Aug. 2024, www.dallasnews.com/news/2024/08/21/ftcs-bid-to-ban-noncompete-agreements-rejected-by-federal-judge-in-texas/. Freedman, Robert. “FTC Exceeded Its Authority with Noncompete Ban, Judge Says.” Legal Dive, Legal Dive, 21 Aug. 2024, www.legaldive.com/news/ftc-exceeded-authority-noncompete-ban-judge-ada-brown/724871/. Stoddart, Michelle, and Elizabeth Schulze. “FTC Ban on Worker Noncompete Agreements Blocked by Federal Judge.” ABC News, ABC News Network, 20 Aug. 2024, abcnews.go.com/Politics/federal-trade-commissions-ban-worker-noncompete-agreements-blocked/story?id=113001832. Hsu, Andrea. “Federal Judge Throws out U.S. Ban on Noncompetes.” NPR, NPR, 21 Aug. 2024, www.npr.org/2024/08/21/g-s1-18376/federal-judge-tosses-ftc-noncompetes-ban. Weatherbed, Jess. “The FTC's Noncompete Agreements Ban Is Blocked.” The Verge, The Verge, 21 Aug. 2024, www.theverge.com/2024/8/21/24225112/ftc-noncompete-agreement-ban-blocked-judge.   “Time is Money” Initiative from Biden-Harris Administration: “Biden-Harris Administration Announces Broad New Actions to Protect Consumers from Billions in Junk Fees.” The White House, The United States Government, 11 Oct. 2023, www.whitehouse.gov/briefing-room/statements-releases/2023/10/11/biden-harris-administration-announces-broad-new-actions-to-protect-consumers-from-billions-in-junk-fees/. Haslett, Cheyenne. “Canceling Subscriptions Should Be as Easy as Signing up, Newly Proposed Federal Rule Says.” ABC News, ABC News Network, 12 Aug. 2024, abcnews.go.com/Politics/canceling-subscriptions-easy-signing-new-federal-rule/story?id=112724977. “Fact Sheet: Biden-Harris Administration Launches New Effort to Crack down on Everyday Headaches and Hassles That Waste Americans' Time and Money.” The White House, The United States Government, 13 Aug. 2024, www.whitehouse.gov/briefing-room/statements-releases/2024/08/12/fact-sheet-biden-harris-administration-launches-new-effort-to-crack-down-on-everyday-headaches-and-hassles-that-waste-americans-time-and-money/. Rosalsky, Greg. “The White House Plan to Stop Companies from Wasting Our Time.” NPR, NPR, 20 Aug. 2024, www.npr.org/sections/planet-money/2024/08/19/g-s1-17604/the-white-house-plan-to-stop-companies-from-wasting-our-time.   CMS Announces First Part D Negotiated Drug Prices: “Factsheet: Medicare Drug Price Negotiation Program.” CMS.Gov, Centers for Medicare & Medicaid Services, Aug. 2023, www.cms.gov/files/document/fact-sheet-medicare-selected-drug-negotiation-list-ipay-2026.pdf. “Fact Sheets Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026.” CMS.Gov, Centers for Medicare & Medicaid Services, 15 Aug. 2024, www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026. “HHS Selects the First Drugs for Medicare Drug Price Negotiation.” HHS.Gov, Department of Health & Human Services, 8 Feb. 2024, www.hhs.gov/about/news/2023/08/29/hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation.html. “Negotiating for Lower Drug Prices Works, Saves Billions.” CMS.Gov, Centers for Medicare & Medicaid Services, 15 Aug. 2024, www.cms.gov/newsroom/press-releases/negotiating-lower-drug-prices-works-saves-billions.   Resources: 2025 Maximum Broker Commissions for Medicare Advantage & Medicare Part D Update: https://link.chtbl.com/ASGN20240808 CMS Announces Part D Savings & 2026 Maximum Fair Prices for First 10 Medicare-Negotiated Drugs: https://ritterim.com/blog/cms-announces-part-d-savings-and-2026-maximum-fair-prices-for-first-10-medicare-negotiated-drugs/ How Insurance Agents Can Use Stories to Sell Insurance: https://link.chtbl.com/ASG613 LinkedIn Basics for Insurance Agents: https://link.chtbl.com/ASG612 Supreme Court Overrules Chevron Deference: https://link.chtbl.com/ASGF20240705   Follow Us on Social! Ritter on Facebook, https://www.facebook.com/RitterIM Instagram, https://www.instagram.com/ritter.insurance.marketing/ LinkedIn, https://www.linkedin.com/company/ritter-insurance-marketing TikTok, https://www.tiktok.com/@ritterim X, https://twitter.com/RitterIM and Youtube, https://www.youtube.com/user/RitterInsurance     Sarah on LinkedIn, https://www.linkedin.com/in/sjrueppel/ Instagram, https://www.instagram.com/thesarahjrueppel/ and Threads, https://www.threads.net/@thesarahjrueppel  Tina on LinkedIn, https://www.linkedin.com/in/tina-lamoreux-6384b7199/

AAF President Douglas Holtz-Eakin and Data Analyst Jacob Jensen join us to discuss reports of slowing inflation, government-“negotiated” drug prices, and campaign promises of price-controlled rent. Apple: podcasts.apple.com/us/podcast/the-…st/id1462191777 Spotify: open.spotify.com/show/7aWwYw3EKPmTqLQMbRGR2e

On Thursday, the Biden administration announced an agreement with drugmakers to reduce the prices of 10 of the most common prescription drugs covered under Medicare Part D. The agreement marks the first time the federal government has negotiated with pharmaceutical companies on drug prices, and the administration estimates the lower prices will save Medicare $6 billion when the deal goes into effect in 2026.You can read today's podcast⁠ ⁠⁠here⁠⁠⁠, our “Under the Radar” story ⁠here and today's “Have a nice day” story ⁠here⁠.You can watch the entire Tangle Live event at City Winery NYC on our YouTube Channel!Check out Episode 5 of our podcast series, The Undecideds. Please give us a 5-star rating and leave a comment!Today's clickables: Quick hits (1:57), Today's story (3:05) Right's take (6:04), Left's take (10:12), Isaac's take (13:56), Questions Answered (19:21), Under the Radar (22:14), Numbers (23:13), Have a nice day (23:51)You can subscribe to Tangle by clicking here or drop something in our tip jar by clicking here. Help share Tangle.I'm a firm believer that our politics would be a little bit better if everyone were reading balanced news that allows room for debate, disagreement, and multiple perspectives. If you can take 15 seconds to share Tangle with a few friends I'd really appreciate it. Email Tangle to a friend here, share Tangle on X/Twitter here, or share Tangle on Facebook here.Take the survey: What do you think of the Medicare negotiations? Let us know!Our podcast is written by Isaac Saul and edited and engineered by Dewey Thomas. Music for the podcast was produced by Diet 75. Our newsletter is edited by Managing Editor Ari Weitzman, Will Kaback, Bailey Saul, Sean Brady, and produced in conjunction with Tangle's social media manager Magdalena Bokowa, who also created our logo. Hosted on Acast. See acast.com/privacy for more information.

Workers for AT&T in Mississippi have joined a strike with others in 9 states calling for better working conditions.Then, the federal government has negotiated lower prices on 10 medications for Medicare patients.Plus, a new report highlights the difficulties educators face trying to keep students in classrooms. Hosted on Acast. See acast.com/privacy for more information.

A daily non-partisan, conversational breakdown of today's top news and breaking news stories This Week's Sponsors:  – Babbel – 60% off Subscription To Learn A New Language – Boll & Branch Bedding & Sheets – 20% Off 1st Order + Free Shipping | CODE: MONEWS   Headlines: – Welcome to Mo News (01:30) – Hackers May Have Stolen The Social Security Numbers Of Most Americans (04:50) – Multiple People Charged In Connection To Matthew Perry's Death (09:00) – Biden and Harris Reunite to Celebrate Deal on Drug Prices (14:50) – The Veep Debate (15:30) – Major Security Operation Underway At Taylor Swift's London Run (19:50) – Jordan Chiles Breaks Silence On Olympic Bronze Medal Controversy (21:30) – Big Trees, A Wooden Ceiling And ‘Therapy' Llamas: What You'll Find At Portland Airport (PDX) (24:00) – Brad Pitt Explains Why He Feels His Acting Career Is on Its “Last Leg” (25:20) – What We're Watching, Reading, Eating (26:30) **Mo News Premium For Members-Only Instagram, Private Podcast: (Click To Join)** — Mosheh Oinounou (@mosheh) is an Emmy and Murrow award-winning journalist. He has 20 years of experience at networks including Fox News, Bloomberg Television and CBS News, where he was the executive producer of the CBS Evening News and launched the network's 24 hour news channel. He founded the @mosheh Instagram news account in 2020 and the Mo News podcast and newsletter in 2022. Jill Wagner (@jillrwagner) is an Emmy and Murrow award- winning journalist. She's currently the Managing Editor of the Mo News newsletter and previously worked as a reporter for CBS News, Cheddar News, and News 12. She also co-founded the Need2Know newsletter, and has made it a goal to drop a Seinfeld reference into every Mo News podcast. Follow Mo News on all platforms: Website: www.mo.news Instagram: https://www.instagram.com/mosheh/ Daily Newsletter: https://www.mo.news/newsletter Youtube: https://www.youtube.com/@monews Twitter: https://twitter.com/mosheh TikTok: https://www.tiktok.com/@mosheh Facebook: https://www.facebook.com/MoshehNews Snapchat: https://t.snapchat.com/pO9xpLY9

Pink Sheet reporter and editors discuss the take-aways from the landmark first Medicare negotiated drug prices and what additional information remains outstanding. More On These Topics From The Pink Sheet Medicare Negotiation Announcement: Discounts From List Price Up To 79%, But Net Savings Unclear: https://pink.citeline.com/PS155128/Medicare-Negotiation-Announcement-Discounts-From-List-Price-Up-To-79-But-Net-Savings-Unclear Medicare Unveils Negotiated Prices, But Near-Term Opportunity To Learn From Process Is Limited: https://pink.citeline.com/PS155129/Medicare-Unveils-Negotiated-Prices-But-NearTerm-Opportunity-To-Learn-From-Process-Is-Limited Round 1 Of US Drug Price Negotiations Suggests Medicare Can Beat Original Part D System: https://pink.citeline.com/PS155130/Round-1-Of-US-Drug-Price-Negotiations-Suggests-Medicare-Can-Beat-Original-Part-D-System The Next 340B Battle: Discount Duplication With Medicare Negotiated Prices: https://pink.citeline.com/PS155043/The-Next-340B-Battle-Discount-Duplication-With-Medicare-Negotiated-Prices

The Inflation Reduction Act gave Medicare historic new power to directly negotiate the prices of some of the costliest prescription drugs. Now the federal agency must grapple with a difficult question: What makes a drug price fair?This week, we revisit our 2023 episode explaining how this negotiation process works and the impact it could have.Guests:Anton Avanceña, PhD, Assistant Professor of Health Outcomes, University of Texas Darius Lakdawalla, PhD, Professor of Pharmaceutical Economics and Public Policy, University of Southern California Lauren Neves, JD, Deputy Vice President, PhRMASteve Pearson, MD, MSc, Founder and President, Institute for Clinical and Economic Review (ICER)Ben Rome, MD, MPH, physician and researcher, Harvard Medical SchoolMeena Seshamani, MD, PhD, Deputy Administrator, Centers for Medicare and Medicaid ServicesLeslie Walker, Senior Producer/Reporter, TradeoffsLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

Beginning in 2026, ten prescription drugs for Medicare recipients will be less expensive.And both major-party candidates for vice president have now agreed to at least one televised debate.Those stories and more in today's evening update. Hosted by Emily Reese. Music by Gary Meister.

Nick's making travel plans.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nick is making travel plans.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Another wildfire in Southern California erupted Monday afternoon, destroying several homes and forcing residents to evacuate. Prescription drug prices are at an all-time high but California is trying to help lower prices. Winner winner chicken dinner! Several LA and Orange county chefs won big last night after attending the Michelin awards for California. Plus more. Support the show: https://laist.com

Donald Trump's speech may strive for unifying America; experts disagree on how best to lower prescription prices; and a look at previous presidential assassination attempts. Plus, swimming the Seine, Cal Thomas on an opportunity for Donald Trump, and the Thursday morning newsSupport The World and Everything in It today at wng.org/donate.Additional support comes from Cedarville University, transforming lives through excellent education and intentional discipleship. Online and on-campus programs at cedarville.edu/WORLDFrom the 2024 Citizen Impact Annual Conference in McDonough [say Mac-DON-uh], Georgia. Tim Goeglein of Focus on the Family is keynote speaker. More at ciconference.us.And from Compelled Podcast. Keith and Melody Green were pioneering Contemporary Christian Music. Then tragedy struck. Episode seventy at compelledpodcast.comCitizen Impact 2024 Annual Conference is Thursday, August 22 in McDonough, Georgia. Focus on the Family's Tim Goeglein is the evening Keynote Speaker. Throughout the afternoon is a great lineup of speakers, with workshops geared for pastors, teens, and all Christians. Visit www.CIconference.us for location, schedule, and registration information.

This month's “Diving Deep” episode, part of the Fixing Healthcare podcast series, takes a close look at two critical topics in the realm of healthcare: OpenAI's newest update, GPT-4o, and ... The post FHC #140: Diving deep into GLP-1 drug prices and ChatGPT's newest update appeared first on Fixing Healthcare.

Patrick Devereux has been a practicing pharmacist since 2005. He is the President and CEO of Family Medical Services which owns 4 retail pharmacies in the Birmingham area. He is also the owner of Happier at Home, an in home senior care franchise. Patrick is passionate about patients being informed about their medicines and using therapies to achieve the desired outcomes. He lives in Hoover with his partner Noel, his three children Joseph, Colin, and Lorelei and their three dogs. Topics covered in this episode:Drug Pricing IssuesPharmacy Benefit ManagersSpread Pricing ConceptIndependent Pharmacy ChallengesDIR FeesFair Meds Act340B PricingPBM and Drug Company NegotiationsExpensive vs. Cheap MedicationsCommunity Pharmacist's RoleDrug Seeking BehaviorsFuture of Drug PricingAlternative Pharmacy Business ModelsFront-End Pharmacy SalesTo learn more about Patrick Devereux and his work, head over to www.fms-pharmacy.com __________________________________________________________Did you know that magnesium is vital for human health? It's involved in more than 300 metabolic processes. And if you're not getting enough magnesium, you could be hurting your sleep, your energy levels, and your ability to lose weight. What I recommend is getting a full spectrum magnesium supplement.I can't say enough about how much magnesium has helped with my sleep, my metabolism, my mood, and overall feelings of calmness. Right now, you can get a free bottle of Organxx's brand new doctor formulated magnesium supplement with the purchase of two. Simply head to https://www.lindseyelmore.com/magnesium7 to get started right now.__________________________________________________________We hope you enjoyed this episode. If you would like to be a supporter of the show, head to www.lindseyelmore.com/supporter Your contribution helps us to bring the best guests into our interview chair. Thank you for listening. Come check us out at www.spreaker.com/show/the-lindsey-elmore-showBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-lindsey-elmore-show--5952903/support.

Bernie Sanders discusses the major currents that will shape America in the coming months and years, the crisis in Gaza, wealth inequality, the climate and more. Vermont poised to become first US state to charge big oil for climate damage & what Trump promised big oil if they give him $1 Billion. Good News Alert! Trump promised Wisconsin jobs - but - Biden actually delivered them.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Washington Post reports on how Big Pharma is fighting Biden’s program to lower prescription-drug costs for seniors. In the New Yorker, one writer examines what it means to fast for Ramadan while Gaza goes hungry. Vox asks: What’s a Saturn return — and why are so many popular musicians singing about it? Today’s episode was guest-hosted by Yasmeen Khan.

For the first time in history, Medicare officials begin negotiating with pharma companies for lower prescription drug prices. Mark Zuckerberg faces angry parents on Capitol Hill. And a sea explorer says he's found Amelia Earhart's long-lost airplane. Learn more about your ad choices. Visit megaphone.fm/adchoices